Deciphera PT receives Investment Bank Analyst Rating Update
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported Q2 EPS of ($0.60), $0.06 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $32.5 million versus...
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported Q1 EPS of ($0.80), $0.10 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $29.2 million versus...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.
|Average||10.78 (-40.45% Downside)|
|No. of Analysts||9|